

REMARKS

Claims 1-38, 42, 43, 58, 59, 73, 79, 82, 89-91, 99, 113-140, 158-170, 176, 177 and 184-222 were previously pending in this application. By this amendment, Applicant is canceling claims 2, 6-10, 32, 126, 140, 161, 184, 199 and 219 without prejudice or disclaimer. Claims 1, 3-5, 11-17, 21, 22, 24, 25, 27-30, 33-38, 42, 59, 73, 79, 91, 113-115, 121, 123, 127, 162, 168, 185, 196, 200, 214, 216 and 220 have been amended. As a result, claims 1, 3-5, 11-31, 33-38, 42, 43, 58, 59, 73, 79, 82, 89-91, 99, 113-125, 127-139, 158-160, 162-170, 176, 177, 185-198, 200-218 and 220-222 are pending for examination with claims 1, 38, 42, 43, 59, 73, 79, 82, 89-91, 99 and 204 being independent claims. No new matter has been added. Applicant reserves the right to pursue any subject matter canceled by this amendment in one or more continuing applications.

Interview with Examiners McIntosh and Wilson

Applicant respectfully thanks Examiners McIntosh and Wilson for conducting an interview with Applicant's representative. During the interview, the outstanding claim rejections and possible claim amendments were discussed; however, no agreement was reached.

Allowable Claims

Applicant thanks the Examiner for indicating that claims 4, 13, 33-35, 127-129, 135-139, 164-167, 200-202, 208-213, 217, 218 and 220-222, would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Objections to the Specification

The Examiner has indicated that the incorporation of essential material in the specification by reference to a foreign application or patent, or to a publication is improper.

Applicant respectfully disagrees with this objection for at least the reasons of record. However, as the claims no longer recite the terms "biotechnology derived heparin" and "chemically modified heparin", Applicant believes this objection is now moot.

Accordingly, withdrawal of this objection is respectfully requested.

Rejections under 35 U.S.C. §112

The Examiner has rejected claims 6-10, 32, 121, 123, 162, 185, 196, 214 and 216 under 35 U.S.C. §112, first paragraph, as failing to comply with the written description requirement. The Examiner has maintained that the claims contain subject matter that was not described in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

While Applicant respectfully disagrees with this rejection for at least the reasons of record, the rejected claims have been canceled or amended to remove the recitation of “biotechnology derived heparin”, “chemically modified heparin” ~~“heparin analogue”~~, ~~“AT-III binding saccharides”~~, and “unfractionated heparin preparations” in the interest of expediting prosecution of this application. The rejection is, therefore, now moot.

Accordingly, withdrawal of this rejection is respectfully requested.

The Examiner has also rejected claims 5-9, 43, 58, 82, 89-90, 116-129, 135-140, 162, 185, 196-202, 214, 216 and 219-220 under 35 U.S.C. §112, second paragraph as being indefinite for failing to particularly point out and distinctly claim the subject matter which Applicant regards as the invention.

In regard to the rejection of the claims for the recitation of the terms “biotechnology derived heparin”, “chemically modified heparin”, “pectin derivative” and “polymer to effect slow release”, Applicant respectfully disagrees for at least the reasons of record. However, in the interest of expediting the prosecution of this application, the recitation of these terms has been removed from the claims. Therefore, the rejection in this regard is now moot.

In regard to the rejection of the claims for the recitation of the term “heparin-like glycosaminoglycan”, Applicant respectfully disagrees for at least the reasons provided herein and of record. Applicant maintains that one of ordinary skill in the art would be reasonably apprised of the scope of the invention as the term is not only described in the specification but was also known to those of ordinary skill in the art at the time the application was filed. To satisfy the written description requirement for definiteness, it is sufficient to show that one of ordinary skill in the art would understand and be able to interpret the rejected term along with the scope of the claim. Applicant maintains that this is the case.

The term has been in use, by those of ordinary skill in the art, since as early as 1969, according to a review of the references available in the PubMed database. In addition, a search of the PubMed database on August 25, 2005 for the terms “heparin-like glycosaminoglycan” or “HLGAG” resulted in the identification of twenty-three (23) different journal articles published prior to the priority date of the instant application. Therefore, at least this many articles containing these terms were published prior to the priority date of this application. A list of the journal articles that were identified is provided for the Examiner’s review. This alone demonstrates that the rejected term was known and understood by those of ordinary skill in the art. Additionally, Applicant provides for the Examiner’s review one example of the references (Rhombert, et al., “Mass spectrometric evidence for the enzymatic mechanism of the depolymerization of heparin-like glycosaminoglycans by heparinase II”, *Proc. Natl. Acad. Sci. USA*, Vol. 95, pp. 12232-12237, October, 1998) to further demonstrate the use and understanding of the term by those of ordinary skill in the art at the time of the filing of the instant application. Rhombert et al., dated October, 1998, clearly show (See, e.g., page 12232, first paragraph) that the term was used in the art. Rhombert et al. also clearly show that there was an understanding of what molecules are encompassed by the term, for instance, by providing the general structure of heparin-like glycosaminoglycans. Heparin-like glycosaminoglycans are described as being complex polysaccharides characterized by a disaccharide repeat unit of a uronic acid (either L-iduronic acid or D-glucuronic acid), which is linked 1-4 to a glucosamine. This description shows that the structure of heparin-like glycosaminoglycans was known and readily recognizable by those of ordinary skill in the art.

As heparin-like glycosaminoglycans are demonstrated to have been known to those of ordinary skill in the art at the time of the filing of the instant application, Applicant maintains that one of ordinary skill in the art would understand what molecules are considered to be heparin-like glycosaminoglycans and would, therefore, recognize the scope of the rejected claims that recite this term.

Applicant notes that claim 5 was included in the listing of rejected claims. However, it is not clear why this claim was included in this rejection, as reasons for the rejection of this claim were not provided in the Examiner’s arguments. Applicant believes that this claim was mistakenly included in the listing of claims for this rejection.

Accordingly, based on the above, withdrawal of this rejection is respectfully requested.

Rejections Under 35 U.S.C. §102

The Examiner has rejected claims 1-3, 5, 8, 11, 12, 14-32, 36-38, 42, 43, 58, 59, 73, 79, 89-91, 99, 113-119, 121-123, 125, 126, 130-134, 158-163, 168-170, 176, 177, 184-198, 203-207, 214-216 and 218 under 35 U.S.C. §102(b) as being anticipated by Illum et al. (WO 97/35562).

Applicant respectfully disagrees for the reasons provided herein and of record. However, in the interest of expediting the prosecution of the instant application, the claims have been amended. Further, Applicant notes that Illum et al. do not teach particles having an aerodynamic diameter of 10 microns. Instead, the particles of Illum et al. are described as having an aerodynamic diameter of less than 10 microns (See, e.g., page 4, lines 5-8 and page 10, lines 22-24). Applicant also notes that Illum et al. do not teach dry unformulated heparin-like glycosaminoglycan particles, nor do Illum et al. teach preparations of unformulated dry glycosaminoglycans in combination with formulated glycosaminoglycans, as provided in Applicant's amended claims. In order for Illum et al. to be anticipatory in this regard, the reference must provide a direct teaching of such particles or preparations. Applicant maintains that the Illum et al. reference fails to meet this requirement.

Accordingly, withdrawal of this rejection is respectfully requested.

Serial No.: 09/982,548
Conf. No.: 7782

- 23 -


Art Unit: 1623

CONCLUSION

A Notice of Allowance is respectfully requested. The Examiner is requested to call the undersigned at the telephone number listed below if this communication does not place the case in condition for allowance.



If this response is not considered timely filed and if a request for an extension of time is otherwise absent, Applicant hereby requests any necessary extension of time. If there is a fee occasioned by this response, including an extension fee, that is not covered by an enclosed check, please charge any deficiency to Deposit Account No. 23/2825.

Respectfully submitted,



Janice A. Vatland, Reg. No. 52,318
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2206
Telephone: (617) 646-8000

Docket No.: M0656.70070US00
Date: August 25, 2005
x08/25/05x



All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals B

Search PubMed

for hltag

Go Clear Save S

Limits Preview/Index History Clipboard Details
Display Summary Show 20 Sort by Send to

About Entrez

Text Version

All: 11 Review: 0

Items 1 - 11 of 11

One page.

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

Special Queries

LinkOut

My NCBI (Cubby)

Related Resources

Order Documents

NLM Mobile

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

☐ 1: [Naggar EF, Costello CE, Zaia J.](#)

[Related Articles, Links](#)



Competing fragmentation processes in tandem mass spectra of heparin-like glycosaminoglycans.

J Am Soc Mass Spectrom. 2004 Nov;15(11):1534-44.

PMID: 15519220 [PubMed - indexed for MEDLINE]

☐ 2: [Natke B, Venkataraman G, Nugent MA, Sasisekharan R.](#)

[Related Articles, Links](#)



Heparinase treatment of bovine smooth muscle cells inhibits fibroblast growth factor-2 binding to fibroblast growth factor receptor but not FGF-2 mediated cellular proliferation.

Angiogenesis. 1999;3(3):249-57.

PMID: 14517424 [PubMed]

☐ 3: [Sasisekharan R, Ernst S, Venkataraman G.](#)

[Related Articles, Links](#)



On the regulation of fibroblast growth factor activity by heparin-like glycosaminoglycans.

Angiogenesis. 1997;1(1):45-54.

PMID: 14517393 [PubMed - as supplied by publisher]

☐ 4: [Zaia J, Costello CE.](#)

[Related Articles, Links](#)



Tandem mass spectrometry of sulfated heparin-like glycosaminoglycan oligosaccharides.

Anal Chem. 2003 May 15;75(10):2445-55.

PMID: 12918989 [PubMed - indexed for MEDLINE]

☐ 5: [Kwan CP, Venkataraman G, Shriver Z, Raman R, Liu D, Qi Y, Varticovski L, Sasisekharan R.](#)

[Related Articles, Links](#)



Probing fibroblast growth factor dimerization and role of heparin-like glycosaminoglycans in modulating dimerization and signaling.

J Biol Chem. 2001 Jun 29;276(26):23421-9. Epub 2001 Apr 5.

PMID: 11292822 [PubMed - indexed for MEDLINE]

☐ 6: [Shriver Z, Raman R, Venkataraman G, Drummond K, Turnbull J, Toida T, Linhardt R, Biemann K, Sasisekharan R.](#)

[Related Articles, Links](#)



Sequencing of 3-O sulfate containing heparin decasaccharides with a partial antithrombin III binding site.


Proc Natl Acad Sci U S A. 2000 Sep 12;97(19):10359-64.


PMID: 10984531 [PubMed - indexed for MEDLINE]


☐ 7: [Venkataraman G, Shriver Z, Raman R, Sasisekharan R.](#)

[Related Articles, Links](#)


Sequencing complex polysaccharides.

 Science. 1999 Oct 15;286(5439):537-42.
PMID: 10521350 [PubMed - indexed for MEDLINE]


 **8:** [Padèra R, Venkataraman G, Berry D, Godavarti R, Sasisekharan R.](#) Related Articles, Links

 FGF-2/fibroblast growth factor receptor/heparin-like glycosaminoglycan interactions: a compensation model for FGF-2 signaling.
FASEB J. 1999 Oct;13(13):1677-87.
PMID: 10506571 [PubMed - indexed for MEDLINE]


 **9:** [Venkataraman G, Raman R, Sasisekharan V, Sasisekharan R.](#) Related Articles, Links

 Molecular characteristics of fibroblast growth factor-fibroblast growth factor receptor-heparin-like glycosaminoglycan complex.
Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3658-63.
PMID: 10097093 [PubMed - indexed for MEDLINE]





 **10:** [Venkataraman G, Shriver Z, Davis JC, Sasisekharan R.](#) Related Articles, Links

 Fibroblast growth factors 1 and 2 are distinct in oligomerization in the presence of heparin-like glycosaminoglycans.
Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):1892-7.
PMID: 10051565 [PubMed - indexed for MEDLINE]

 **11:** [Ernst S, Rhomberg AJ, Biemann K, Sasisekharan R.](#) Related Articles, Links

 Direct evidence for a predominantly exolytic processive mechanism for depolymerization of heparin-like glycosaminoglycans by heparinase I.
Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4182-7.
PMID: 9539710 [PubMed - indexed for MEDLINE]

Display Summary

 Show 20  Sort by  Send to 



[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Aug 23 2005 04:56:19



All Databases

PubMed

Nucleotide

Protein

Genome

Structure

OMIM

PMC

Journals

B

Search PubMed

for "heparin-like glycosaminoglycan"

Go

Clear

Save S

Limits

Preview/Index

History

Clipboard

Details

Display Summary

Show

20

Sort by

Send to

About Entrez

Text Version

All: 22

Review: 1



Items 1 - 20 of 22

Page

1

of 2 Next

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

Special Queries

LinkOut

My NCBI (Cubby)

Related Resources

Order Documents

NLM Mobile

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

☐ 1: [Zaia J, Costello CE.](#)[Related Articles, Links](#)

Tandem mass spectrometry of sulfated heparin-like glycosaminoglycan oligosaccharides.

Anal Chem. 2003 May 15;75(10):2445-55.

PMID: 12918989 [PubMed - indexed for MEDLINE]

☐ 2: [Kojima T.](#)[Related Articles, Links](#)

Targeted gene disruption of natural anticoagulant proteins in mice.

Int J Hematol. 2002 Aug;76 Suppl 2:36-9. Review.

PMID: 12430897 [PubMed - indexed for MEDLINE]

☐ 3: [Marks RM, Lu H, Sundaresan R, Toida T, Suzuki A, Imanari T, Hernaiz MJ, Linhardt RJ.](#)[Related Articles, Links](#)

Probing the interaction of dengue virus envelope protein with heparin: assessment of glycosaminoglycan-derived inhibitors.

J Med Chem. 2001 Jun 21;44(13):2178-87.

PMID: 11405655 [PubMed - indexed for MEDLINE]

☐ 4: [Ali S, Palmer AC, Banerjee B, Fritchley SJ, Kirby JA.](#)[Related Articles, Links](#)

Examination of the function of RANTES, MIP-1alpha, and MIP-1beta following interaction with heparin-like glycosaminoglycans.

J Biol Chem. 2000 Apr 21;275(16):11721-7.

PMID: 10766793 [PubMed - indexed for MEDLINE]

☐ 5: [Feldman SA, Hendry RM, Beeler JA.](#)[Related Articles, Links](#)

Identification of a linear heparin binding domain for human respiratory syncytial virus attachment glycoprotein G.

J Virol. 1999 Aug;73(8):6610-7.

PMID: 10400758 [PubMed - indexed for MEDLINE]

☐ 6: [Venkataraman G, Raman R, Sasisekharan V, Sasisekharan R.](#)[Related Articles, Links](#)

Molecular characteristics of fibroblast growth factor-fibroblast growth factor receptor-heparin-like glycosaminoglycan complex.

Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3658-63.

PMID: 10097093 [PubMed - indexed for MEDLINE]

☐ 7: [Venkataraman G, Shriver Z, Davis JC, Sasisekharan R.](#)[Related Articles, Links](#)

Fibroblast growth factors 1 and 2 are distinct in oligomerization in the presence of heparin-like glycosaminoglycans.

Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):1892-7.

PMID: 10051565 [PubMed - indexed for MEDLINE]


-  **8:** [Liu D, Shriver Z, Godavarti R, Venkataraman G, Sasisekharan R.](#) Related Articles, Links



The calcium-binding sites of heparinase I from *Flavobacterium heparinum* are essential for enzymatic activity.

J Biol Chem. 1999 Feb 12;274(7):4089-95.

PMID: 9933602 [PubMed - indexed for MEDLINE]


-  **9:** [Rhombert AJ, Shriver Z, Biemann K, Sasisekharan R.](#) Related Articles, Links



Mass spectrometric evidence for the enzymatic mechanism of the depolymerization of heparin-like glycosaminoglycans by heparinase II.

Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12232-7.

PMID: 9770469 [PubMed - indexed for MEDLINE]

-  **10:** [Kainulainen V, Wang H, Schick C, Bernfield M.](#) Related Articles, Links



Syndecans, heparan sulfate proteoglycans, maintain the proteolytic balance of acute wound fluids.

J Biol Chem. 1998 May 8;273(19):11563-9.

PMID: 9565572 [PubMed - indexed for MEDLINE]


-  **11:** [Shriver Z, Hu Y, Sasisekharan R.](#) Related Articles, Links



Heparinase II from *Flavobacterium heparinum*. Role of histidine residues in enzymatic activity as probed by chemical modification and site-directed mutagenesis.

J Biol Chem. 1998 Apr 24;273(17):10160-7.

PMID: 9553064 [PubMed - indexed for MEDLINE]


-  **12:** [Baenziger NL, Mack P, Jong YJ, Dalemar LR, Perez N, Lindberg C, Wilhelm B, Haddock RC.](#) Related Articles, Links



An environmentally regulated receptor for diamine oxidase modulates human endothelial cell/fibroblast histamine degradative uptake.

J Biol Chem. 1994 May 27;269(21):14892-8.

PMID: 8195119 [PubMed - indexed for MEDLINE]

-  **13:** [Nishinaga M, Shimada K.](#) Related Articles, Links



[Heparan sulfate proteoglycan of endothelial cells: homocysteine suppresses anticoagulant active heparan sulfate in cultured endothelial cells]

Rinsho Byori. 1994 Apr;42(4):340-5. Japanese.

PMID: 8176841 [PubMed - indexed for MEDLINE]

-  **14:** [Visentin GP, Ford SE, Scott JP, Aster RH.](#) Related Articles, Links



Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells.

J Clin Invest. 1994 Jan;93(1):81-8.

PMID: 8282825 [PubMed - indexed for MEDLINE]


-  **15:** [Nishinaga M, Ozawa T, Shimada K.](#) Related Articles, Links



Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells.

J Clin Invest. 1993 Sep;92(3):1381-6.

PMID: 8376590 [PubMed - indexed for MEDLINE]

 **16:** [Horie S, Ishii H, Kazama M.](#)

[Related Articles](#), [Links](#)



Heparin-like glycosaminoglycan is a receptor for antithrombin III-dependent but not for thrombin-dependent prostacyclin production in human endothelial cells.

Thromb Res. 1990 Sep 15;59(6):895-904.

PMID: 2175954 [PubMed - indexed for MEDLINE]

 **17:** [Parrish JJ, Susko-Parrish JL, Handrow RR, Sims MM, First NL.](#)

[Related Articles](#), [Links](#)



Capacitation of bovine spermatozoa by oviduct fluid.

Biol Reprod. 1989 May;40(5):1020-5.

PMID: 2765607 [PubMed - indexed for MEDLINE]

 **18:** [Poulsen JH, Jensen IM, Petersen U.](#)


[Related Articles](#), [Links](#)



D-[3H]glucosamine labelling of epidermal and dermal glycosaminoglycans in cultured human skin.

J Clin Chem Clin Biochem. 1988 Mar;26(3):123-33.

PMID: 3385361 [PubMed - indexed for MEDLINE]

 **19:** [Baird A, Ling N.](#)


[Related Articles](#), [Links](#)



Fibroblast growth factors are present in the extracellular matrix produced by endothelial cells in vitro: implications for a role of heparinase-like enzymes in the neovascular response.

Biochem Biophys Res Commun. 1987 Jan 30;142(2):428-35.

PMID: 2434094 [PubMed - indexed for MEDLINE]

 **20:** [van Heusden MC, van der Horst DJ, van Doorn JM, Beenakkers AM.](#)

[Related Articles](#), [Links](#)



Partial purification of locust flight muscle lipoprotein lipase (LpL): apparent differences from mammalian LpL.

Comp Biochem Physiol B. 1987;88(2):523-7.

PMID: 3427899 [PubMed - indexed for MEDLINE]

Items 1 - 20 of 22

Page 1

of 2 [Next](#)

Display [Summary](#)



Show

20



Sort by



Send to



[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Aug 23 2005 04:56:19

Mass spectrometric evidence for the enzymatic mechanism of the depolymerization of heparin-like glycosaminoglycans by heparinase II

ANDREW J. RHOMBERG*, ZACHARY SHRIVER†, KLAUS BIEMANN*, AND RAM SASISEKHARAN†‡

*Department of Chemistry, and †Division of Bioengineering and Environmental Health, Massachusetts Institute of Technology, Cambridge, MA 02139

Contributed by Klaus Biemann, August 24, 1998

ABSTRACT Heparin-like glycosaminoglycans, acidic complex polysaccharides present on cell surfaces and in the extracellular matrix, regulate important physiological processes such as anticoagulation and angiogenesis. Heparin-like glycosaminoglycan degrading enzymes or heparinases are powerful tools that have enabled the elucidation of important biological properties of heparin-like glycosaminoglycans *in vitro* and *in vivo*. With an overall goal of developing an approach to sequence heparin-like glycosaminoglycans using the heparinases, we recently have elaborated a mass spectrometry methodology to elucidate the mechanism of depolymerization of heparin-like glycosaminoglycans by heparinase I. In this study, we investigate the mechanism of depolymerization of heparin-like glycosaminoglycans by heparinase II, which possesses the broadest known substrate specificity of the heparinases. We show here that heparinase II cleaves heparin-like glycosaminoglycans endolytically in a nonrandom manner. In addition, we show that heparinase II has two distinct active sites and provide evidence that one of the active sites is heparinase I-like, cleaving at hexosamine-sulfated iduronate linkages, whereas the other is presumably heparinase III-like, cleaving at hexosamine-glucuronate linkages. Elucidation of the mechanism of depolymerization of heparin-like glycosaminoglycans by the heparinases and mutant heparinases could pave the way to the development of much needed methods to sequence heparin-like glycosaminoglycans.

Heparin-like glycosaminoglycans (HLGAGs) are one of the major components of the extracellular matrix and are present at the cell surface as part of proteoglycans (1, 2). HLGAGs are complex polysaccharides characterized by a disaccharide repeat unit of a uronic acid (either L-iduronic acid or D-glucuronic acid) which is linked 1–4 to a glucosamine (3). The modification of the functional groups of the sugar units (i.e., 2-O sulfate on the uronic acid and 3-O, 6-O, and N-sulfation of the hexosamine) (4), taken together with the variation in the chain length make HLGAGs the most acidic and heterogenous biopolymers. Together, these modifications allow for a wide array of HLGAG sequences and present a daunting challenge to understanding how certain sequences of HLGAGs elicit a biological response.

Of importance then is the development of molecular tools to study the *in vivo* roles of HLGAG sequences. One such strategy, being developed in our laboratories, is to use HLGAG degrading enzymes, or heparinases, to investigate the role and composition of biologically relevant HLGAG sequences. Three heparinases (I, II, and III) have been isolated from *Flavobacterium heparinum*; they differ from one another in terms of their size, molecular characteristics, and substrate

specificities (5). By using these heparinases we have provided evidence for HLGAG involvement in fundamental biological processes such as angiogenesis (6) and development (7). While the heparinases have shown their use in delineating specific biological roles for HLGAG sequences, it is also possible that these enzymes can be used for the sequencing of HLGAG polymers when used in combination with a high precision analytical technique, such as matrix-assisted laser desorption ion mass spectrometry (MALDI MS), to identify enzyme-generated saccharide intermediates (8).

As a step toward the development of a sequencing protocol for HLGAGs, we recently have demonstrated that MALDI MS in combination with capillary electrophoresis can be used to successfully identify saccharide intermediates generated upon cleavage of defined oligosaccharides by heparinase I (9). We used this methodology to elucidate the mechanism of HLGAG depolymerization by heparinase I and discovered that it acts predominantly by an exolytic, processive mechanism, depolymerizing its substrate by binding HLGAG oligosaccharides and cleaving linkages starting from the nonreducing end of the polymer (10).

Heparinase II, another of the heparinases from *F. heparinum*, has the broadest substrate specificity of the three heparinases (11, 12). Heparinase II is able to cleave a wide range of disaccharide repeat units; indeed, linkages within HLGAG polysaccharides that are resistant to cleavage by heparinase I or III are cleaved by heparinase II (13–15). This suggested to us that heparinase II is an attractive candidate for developing a practical sequencing methodology for HLGAGs. To further develop heparinase II as an analytical tool for sequencing, we undertook an investigation of the mechanism of depolymerization of HLGAGs by heparinase II.

MATERIALS AND METHODS

Materials. Substrate H1 was a gift from D. Tyrrell of Glycomed (Alameda, CA). Substrates O2, D3, and D4 were kindly provided by R. J. Linhardt after repurification by R. Hildeman (University of Iowa). P14 was a gift from Organon (P. Jacobs). Oligosaccharides were dissolved in deionized water at concentrations of 10–35 μ M. Sucrose octasulfate was added as an internal standard where indicated. Heparinase II was diluted to a final concentration of 50 nM in a buffer containing 10 μ M ovalbumin, 1 μ M dextran sulfate, 50% glycerol, and 20 mM phosphate buffer (pH 7.0).

Enzymatic Purification. Heparinase II from *F. heparinum* was purified as described (16). In addition, recombinant heparinase II and the heparinase mutant protein, C348A, where cysteine-348 is changed to alanine were expressed in

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.

© 1998 by The National Academy of Sciences 0027-8424/98/9512232-6\$2.00/0
PNAS is available online at www.pnas.org.

Abbreviations: HLGAGs, heparin-like glycosaminoglycans; MALDI, matrix-assisted laser desorption ionization; MS, mass spectrometry.

‡To whom reprint requests should be addressed at: 16-561, 77 Massachusetts Avenue, Massachusetts Institute of Technology, Cambridge, MA 02139. e-mail: ramnat@mit.edu.

Escherichia coli (17). Protein expression, isolation, and purification was carried out as described (17).

Digests. Digests and mass spectral analyses were carried out as previously reported for heparinase I (9) with the exception that a calcium free buffer was used. Enzyme reactions using wild-type heparinase II derived from *F. heparinum* were performed by adding 1 μ l of enzyme solution to 5 μ l of substrate solution. Each time point was obtained by removing 0.5 μ l of the reaction mixture and adding it to 4.5 μ l of matrix solution. With *E. coli*-derived recombinant heparinase II (both wild-type and the C348A mutant), 1 μ l of enzyme solution was added to 1 μ l of substrate solution. In this case, the reaction was quenched after 60 min via the addition of 8 μ l of matrix. All digests, whether with *F. heparinum*- or *E. coli*-derived recombinant heparinase II, were carried out at room temperature.

Derivatization. Chemical derivatization of decasaccharide D3 was carried out by reacting 5 μ l of oligosaccharide solution with 5 μ l of 50 mM semicarbazide and 60 mM Tris/acetic acid (pH 5.0) for 18 hr at 30°C. Before digestion with the enzyme, the pH was adjusted to 7.0 by the addition of 1 μ l of 50 mM Tris.

MS. A saturated solution of caffeic acid (\approx 12 mg/ml in 30% acetonitrile/water) was used as the matrix solution. Seeded surfaces were prepared by using a modification (9) of the method developed by Xiang and Beavis (18). A 2-fold molar excess of peptide (arg-gly)₁₉arg, isolated as the free base, was premixed with matrix before addition to the oligosaccharide solution (19). A 1- μ l aliquot of sample/matrix mixture was

deposited on the seeded stainless steel surface. After the formation of a polycrystalline layer, excess liquid was rinsed off with deionized water. MALDI MS spectra were acquired in the linear mode by using a Perseptive Biosystems (Framingham, MA) Voyager Elite reflectron time-of-flight instrument fitted with a 337-nm laser. Delayed extraction (20) was used to increase resolution (22 kV, grid at 93%, guide wire at 0.15%, pulse delay 150 ns, low mass gate at 1,000, 128 shots averaged). Mass spectra were calibrated externally by using signals for protonated (arg-gly)₁₉arg and its complex with oligosaccharide H1.

RESULTS

Does Heparinase II Act Exolytically or Endolytically? Table 1 lists the abbreviations, full sequences, and complexed [with (arg-gly)₁₉arg] *m/z* values of all substrates and products that appear in this study. Fig. 1 lists the substrates used in this study and outlines the possible cleavage pathways of these substrates when acted on by heparinase II.

Unlike either heparinase I or heparinase III, heparinase II has a broad substrate specificity, cleaving both sulfated and unsulfated substrates under nonforcing conditions (i.e., with enzyme-to-substrate ratios of 1:100 to 1:1,000). It was assumed that the relative susceptibility of scissile bonds should depend on the nature of residues flanking the glycosidic linkage. Therefore, two oligosaccharides, H1 and D3, containing only sulfated iduronate-hexosamine linkages, were used as substrates for the initial experiments. In this way, the

Table 1. *m/z* of peptide/oligosaccharide complexes used in this study

Substrates (1–4, 14) and products (5–13, 15–25)		Underivatized	Derivatized
Monosaccharides			
M24	H _{NAC,6S}	(4,742.19)	
Disaccharides			
Di6	Δ U _{2S} -H _{NS,6S}	4,804.23	4,859.25
Di15	I _{2S} -H _{NS,6S}	4,822.26	
Di17	Δ U _{2S} -Man _{6S}	(4,709.15)	
Di18	Δ U-H _{NS,6S}	(4,724.17)	
Di23	Δ U _{2S} -H _{NS,6S,OMe}	4,822.26	
Trisaccharides			
Tr22	H _{NAC,6S} -G-H _{NS,6S,3S}	5,143.49	
Tetrasaccharides			
T5	Δ U _{2S} -H _{NS,6S} -I _{2S} -H _{NS,6S}	5,381.72	5,437.79
T7	Δ U _{2S} -H _{NS,6S} -I _{2S} -Man _{6S}	5,286.63	
T9	Δ U _{2S} -H _{NS,6S} -G-H _{NS,6S}	5,301.65	
T16	I _{2S} -H _{NS,6S} -I _{2S} -H _{NS,6S}	(5,399.74)	
T19	Δ U _{2S} -H _{NS,6S} -I-H _{NAC,6S}	5,263.63	
T25	Δ U-H _{NS,6S,3S} -I _{2S} -H _{NS,6S,OMe}	(5,410.72)	
Pentasaccharides			
P14	H _{NAC,6S} -G-H _{NS,6S,3S} -I _{2S} -H _{NS,6S,OMe}	5,734.99	
Hexasaccharides			
H1	I _{2S} -H _{NS,6S} -I _{2S} -H _{NS,6S} -I _{2S} -Man _{6S}	5,882.13	
H8	Δ U _{2S} -H _{NS,6S} -[I _{2S} -H _{NS,6S}] ₂	5,959.20	6,015.27
H10	Δ U _{2S} -H _{NS,6S} -I _{2S} -H _{NS,6S} -G-H _{NS,6S}	5,879.13	
H12	Δ U _{2S} -H _{NS,6S} -I-H _{NAC,6S} -H _{NS,6S,3S}	5,841.11	
H20	Δ U-H _{NS,6S,3S} -I _{2S} -H _{NS,6S} -I _{2S} -H _{NS,6S}	5,959.20	
Octasaccharides			
O2	Δ U _{2S} -H _{NS,6S} -I _{2S} -H _{NS,6S} -I _{2S} -H _{NS,6S} -G-H _{NS,6S}	6,456.61	
O11	Δ U _{2S} -H _{NS,6S} -[I _{2S} -H _{NS,6S}] ₃	6,536.68	
O13	Δ U _{2S} -H _{NS,6S} -I-H _{NAC,6S} -G-H _{NS,6S,3S} -I _{2S} -H _{NS,6S}	6,536.68	6,592.75
O21	Δ U-H _{NAC,6S} -G-H _{NS,6S,3S} -I _{2S} -H _{NS,6S} -I _{2S} -H _{NS,6S}	6,536.69	
Decasaccharides			
D3	Δ U _{2S} -H _{NS,6S} -[I _{2S} -H _{NS,6S}] ₄	(6,996.07)	7,052.14
D4	Δ U _{2S} -H _{NS,6S} -I-H _{NAC,6S} -G-H _{NS,6S,3S} -[I _{2S} -H _{NS,6S}] ₂	(7,114.16)	

2S, 3S, and 6S, 2-O, 3-O, or 6-O sulfation, (respectively); NS and NAc, N-sulfation and N-acetylation of the glucosamine.

*Saccharides not observed are in parentheses. Oligosaccharides are abbreviated as follows: I, α -L-iduronic acid; G, β -D-glucuronic acid; Δ U, I or G with an unsaturated C4–C5 bond; H, α -D-2-deoxy,2-aminoglucose; and Man, anhydromannitol.






Hexasaccharide H1**Decasaccharide D3****Octasaccharide O2****Decasaccharide D4****Pentasaccharide P14**

FIG. 1. Schematic representation of reactions of heparinase II digestion of the saccharides H1, D3(d), O2, D4, and P14. Substrates and products refer to Table 1.

mode of action of heparinase II (i.e., whether the enzyme acts exolytically or endolytically, processively or nonprocessively) could be investigated independently of any potential

bias introduced by the chemical composition of the glycosidic linkage.

Upon heparinase II digestion of H1, tetrasaccharide T7 was observed concomitant with a decrease in the H1 signal, but T16 was not observed (Fig. 2). Thus, heparinase II cleaves H1 only at the scissile bond closest to the nonreducing end (Fig. 1, reaction 1.1). This result suggested that heparinase II might be exolytic; however, the absence of T16 (reaction pathway 1.2) also could be the result of an end group effect (i.e., the anhydromannitol moiety present at the reducing end could prevent the enzyme from cleaving linkage 1.2). Thus, to determine whether heparinase II acts exolytically, the decasaccharide D3 was treated with this enzyme. A number of intermediates were identified in the product profile (Fig. 3A). Octa- (O11), hexa- (H8), and tetrasaccharides (T5) were observed as intermediates. Furthermore, the amount of H8 produced was roughly equivalent to that of T5. Importantly, the amount of T5 remained relatively constant over time, indicating that the susceptibility of linkages to heparinase II is dependent on the size of the substrate. These results unambiguously show that heparinase II is an endolytic enzyme—i.e., for heparinase II, cleavage is possible at internal linkages (2.2 or 2.3 in D3) as well as external linkages (2.1 and 2.4 in D3).

To confirm the results obtained with D3 and to establish whether heparinase II is a random, endolytic enzyme, D3 was derivatized with semicarbazide to introduce a mass tag at the reducing end. When derivatized D3 (D3^d) was digested with heparinase II, only nonderivatized octa- (O11, but not O11^d) and hexasaccharide (H8, but not H8^d) were observed (Fig. 3B and Fig. 1, reaction pathways 2.3 and 2.4). In addition, derivatized tetrasaccharide (T5^d) and both derivatized (Di6^d) and nonderivatized (Di6) disaccharide were observed. In the case of D3^d then, both H8 and O11 must be fragments derived from heparinase II cleavage and product release from the reducing end of D3^d. Taken together, the presence of H8 and O11, coupled with the absence of H8^d and O11^d, indicate that the mechanism of action of heparinase II is not random (see Discussion for further interpretation). Thus, the digestion




FIG. 2. MALDI MS spectra of H1 digestion by heparinase II. P refers to the protonated peptide (arg-gly)₁₉ arg. Sucrose octasulfate, H1, and T7 refer to the protonated complexes of peptide with sucrose octasulfate and with the oligosaccharide substrates and products (Table 1). (A) Mass spectrum profile of starting material H1. (B) Product profile after 60 min of digestion with heparinase II.




FIG. 3. (A) MALDI MS digestion profile of a 60-min heparinase II digestion of D3. Present in the product profile are O11, H8, T5, and Di6 (see Fig. 1 for reactions). (B) Heparinase II digestion of D3 after modification at the reducing end with semicarbazide (+57.06 mass units). Products with the mass tag are designated with a "d" (i.e., T5^d and Di6^d).

profiles of H1, D3, and D3^d indicate that heparinase II is a nonrandom, endolytic enzyme.

Evidence for the Presence of Two Active Sites in Heparinase II. We sought further to corroborate the above findings with H1, D3, and D3^d by using a substrate with more than one type of linkage. To this end, we investigated the mode of action of heparinase II on O2 that contains an unsulfated glucuronate at the reducing end. The dominant product observed in the initial time points of the digestion profile of O2 was H8 (data not shown), indicating cleavage at the unsulfated glucuronate (Fig. 1, reaction 3.3). This finding indicated that heparinase II was more efficient at cleaving linkages containing an unsulfated glucuronate than those containing a sulfated iduronate, even though this linkage is located next to the reducing terminus in O2 (Fig. 4). The substrate also was cleaved at sulfated iduronic acids, resulting in H10, T5, and T9 (reactions 3.1 and 3.2). Upon prolonged digestion the intermediate H8 was converted to T5 (reaction 3.3) and ultimately to Di6. This result further strengthens the notion that heparinase II, while endolytic, displays a nonrandom process of cleavage.

The strong preference of heparinase II for the unsulfated glucuronate-containing linkage of O2 is consistent with the observation that heparinase II might contain two active sites, one of which is heparinase I-like, cleaving primarily heparin-like linkages, whereas the other site is heparinase III-like and cleaves primarily heparan sulfate-like linkages (17). In accordance with this hypothesis, we have identified a particular cysteine residue, cysteine 348, which is critical for the breakdown of heparin but not heparan sulfate by heparinase II (17). Therefore, we used a mutant heparinase II enzyme with this cysteine residue replaced by a nonfunctional alanine, hereafter referred to as the C348A mutant, to determine whether this dual active site model is correct.

Consistent with our hypothesis, H1 (which contains only sulfated iduronate linkages) was resistant to digestion by the C348A mutant (data not shown). In addition, the C348A mutant converted O2 almost exclusively to H8, resulting from cleavage at the unsulfated, glucuronic acid (Fig. 5 and Fig. 1,




FIG. 4. MALDI MS spectra of heparinase II digestion of substrate O2. (A) Initial substrate profile before the introduction of heparinase II. Product profile after 60 min of digestion (B) and after 120 min of digestion (C).

reaction 3.3); a small amount of T5 was also detected, which we interpret to be an impurity (data not shown). Furthermore, extending the digest time did not increase the amount of T5; thus, T9 could have arisen from heparinase II cleavage of a less sulfated impurity, present at $\approx 5\%$ in the O2 substrate. Thus, the heparinase II C348A mutant does not appear to cleave glycosidic linkages flanked by sulfated iduronic acids. These results indicate that the activity of heparinase II or heparin-like and heparan sulfate-like regions of HLGAGs is distinct (see Discussion).

Action of Heparinase II on 3-O-Sulfated Glucosamine. In light of the above data regarding the size-dependent susceptibility of linkages to heparinase II digestion, we attempted to




FIG. 5. MALDI MS spectrum of O2 digestion with the heparinase II C348A mutant. The figure represents the product profile after 120 min of digestion. A control of wild-type recombinant heparinase II was run at the same time. Its product profile at 120 min is identical to that in Fig. 4C.

address the conflicting reports in the literature regarding the susceptibility of linkages proximate to a 3-O-sulfated glucosamine to heparinase II digestion. Previous reports suggest that heparinase II can cleave both scissile bonds flanking the disaccharide unit containing the 3-O-sulfated glucosamine (14). Later, Sugahara *et al.* (15) stated that a 3-O sulfate containing tetrasaccharide was resistant to heparinase II digestion, although most other tetrasaccharides were readily digested by this enzyme. To investigate this apparent discrepancy, we examined the heparinase II-treated digest profile of D4 and P14.

Substrate D4 presents a special case because it contains a 3-O-sulfated glucosamine in addition to an unsulfated glucuronate and an unsulfated iduronate linkage (see Table 1). The primary product of digestion of D4 with heparinase II was H20 (Fig. 6), indicating cleavage at the glycosidic linkage upstream of the 3-O-sulfated glucosamine (Fig. 1, reaction 4.2). Cleavage downstream of the 3-O-sulfated glucosamine (reaction 4.3) also took place, as H12 was observed in the mass spectrum. In addition, the tetrasaccharides T5 and T19 were detected. These results indicated that, within a decasaccharide length substrate, heparinase II was able to cleave linkages flanking a 3-O-sulfated glucosamine residue.

To address the susceptibility of 3-O-sulfated glucosamine to cleavage by heparinase II within a shorter substrate, the product profile of pentasaccharide (P14) was investigated (Fig. 7). It showed that P14 was cleaved exclusively at the scissile bond upstream of the 3-O-sulfated glucosamine (Fig. 1, reaction 5.1). This finding is in contrast to the above results with D4, where linkages both upstream and downstream were cleaved. Together these results point to the fact that the susceptibility of the scissile bond downstream to a 3-O glucosamine depends on the length of the substrate; in decasaccharide fragments or larger, the downstream linkage is susceptible to heparinase II action, whereas in shorter fragments this linkage is relatively resistant to cleavage.

DISCUSSION

Heparinase II Is an Endolytic, Nonrandom Enzyme. The aim of this study was to elucidate the mode of HLGAG depolymerization by heparinase II using well-defined substrates. With sulfated substrates of the general composition $(H_6X, NS-I_{25})_x$, such as H1, D3, and D3^d, heparinase II was found to cleave in an endolytic manner. In addition, the D3^d results clearly show that heparinase II, while endolytic, cleaves sulfated substrates in a nonrandom manner.

No hexasaccharides or octasaccharides derived from cleavage at the nonreducing end (i.e., neither O11^d nor H8^d) were observed when D3^d was digested with heparinase II. In addition, the smallest observed fragment derived from cleavage at the nonreducing end was the tetrasaccharide T5^d. These results clearly indicate that the mode of action of heparinase II is not random, rather the enzyme possesses a bias for certain link-




FIG. 6. MALDI MS spectrum of a heparinase II digestion of D4. The reaction was quenched at 60 min. Notation is similar to that of Fig. 3; chemical composition of products is outlined in Table 1.




FIG. 7. Analysis of the action of heparinase II on the pentasaccharide P14. (A) Profile of the pentasaccharide before introduction of heparinase II. (B) Product profile after 60 min of digestion.

ages. The nonrandom nature of heparinase II depolymerization seems to depend on the size of the substrate as well as the chemical composition of the linkages.

In a previous study, upon incubation of D3^d with heparinase I the digestion profile of D3^d showed only T5^d and Di6 as products (9, 10). This result led us to conclude that heparinase I is an exolytic, processive enzyme that cleaves from the nonreducing to the reducing end. For heparinase II, the absence of derivatized hexa- and octasaccharide, plus the excess of Di6 to Di6^d and the absence of H8^d, indicates that heparinase II cleaves D3^d in a manner similar to heparinase I. Thus, there may be some element of processivity to heparinase II. However, it is also possible that this product profile could be generated by nonrandom cleavage of D3^d, followed by release of the product (which then would be a substrate for another round of cleavage). This interpretation is consistent with the roughly equivalent ratio of T5 to T5^d in the product profile.

That heparinase I and heparinase II have a similar ability to cleave heparin-like regions of HLGAGs is not surprising considering their sequence similarity in functionally important regions. Both possess a Cardin-Weintraub consensus sequence. For heparinase II, the sequence reads ⁴⁴⁴FFKRTIAH⁴⁵¹ (21), which is homologous to the heparin binding/active site region of heparinase I: ¹⁹⁶IFKRNIAH²⁰³. In addition, evidence exists that His-451 plays a role in heparinase II similar to that which His-203 plays in heparinase I (21) for the breakdown of heparin. Thus, this sequence may represent part of the active site in heparinase II that is heparinase I-like. However, some fundamental aspects of the cleavage of heparin-like regions of HLGAGs by heparinase II must differ from heparinase I, because the enzymatic digest profile of substrates such as D3^d are different for the two enzymes. In addition, heparinase II possesses the ability to cleave heparan sulfate-like regions of HLGAGs, which heparinase I cannot.

Heparinase II Possesses Two Active Sites. A different mode of action was observed for heparinase II when an unsulfated glucuronate residue was present in the substrate. Heparinase

II was found to exhibit a strong preference for unsulfated glucuronate linkages, which is consistent with the higher activity of heparinase II toward heparan sulfate, which is largely composed of unsulfated glucuronate as the uronate component. Cleavage at these sites appears to be independent of cleavage at sites containing sulfated iduronate linkages. Thus, it is proposed that heparinase II has a second active site domain, different from the one described above. The first site (site 1) cleaves heparin-like linkages (i.e., highly sulfated linkages flanked by iduronate moieties); the other site (site 2) cleaves primarily heparan sulfate-like regions (i.e., unsulfated linkages flanked by glucuronate moieties). Furthermore, we have identified a mutant of heparinase II, C348A, where the activity of site 1 has been greatly reduced or eliminated, whereas the activity associated with site 2 is intact. Because of the limited availability of substrates, we cannot at this time determine the mode of action of heparinase II at site 2.

The Activity of Heparinase II Depends on the Size of the Substrate. With several of the substrates tested in this study it was apparent that the susceptibility of a glycosidic linkage depended on the size of the substrate. With D3^d, the persistence of T5^d indicates that the cleavage of oligosaccharides by heparinase II is slowed significantly when the substrate has been degraded to generate a tetrasaccharide, similar to what has been observed for heparinase I.

The size-dependent susceptibility of a linkage to heparinase II cleavage also was seen when we examined the ability of heparinase II to cleave saccharides containing a 3-O-sulfated glucosamine. Two substrates were used: one (D4), a decasaccharide; the other (P14), a pentasaccharide. We found that the susceptibility of linkages downstream of 3-O-sulfated glucosamine is influenced by the length of the oligosaccharide chain, with this linkage being susceptible when present in D4 but resistant when present in P14. Together, these results could resolve the controversy regarding the susceptibility of linkages downstream of a 3-O-sulfated glucosamine to heparinase II cleavage. In short, Linhardt *et al.* (14) were able to observe cleavage by heparinase II at sites both upstream and downstream of 3-O-sulfated glucosamine of longer oligosaccharides, whereas Sugahara and coworkers (15) did not observe cleavage at linkages downstream of 3-O sulfate in a tetrasaccharide. Our results clearly show that both observations are consistent with the mode of heparinase II activity as outlined in this study.

In summary, we have shown that heparinase II contains two active sites. Active site 1 is similar to the active site of heparinase I, except for the fact that it processes substrates

endolytically, rather than exolytically. Active site 1 cleaves primarily sulfated linkages, whereas site 2 cleaves primarily unsulfated linkages. This study provides a framework for further investigations into the two active sites of heparinase II, exploiting it for the use of sequencing HLGAG oligosaccharides.

We thank Drs. R. Hileman, R. J. Linhardt, D. Tyrrell, and P. Jacobs for oligosaccharides. We also thank the National Institutes of Health (Grants GM57073 to R.S. and GM05472 to K.B.) and the Austrian-American Educational Commission (to A.J.R.) for funding.

1. Kjellen, L. & Lindahl, U. (1991) *Annu. Rev. Biochem.* **60**, 443–475.
2. Jackson, R. L., Busch, S. J. & Cardin, A. D. (1991) *Physiol. Rev.* **71**, 481–539.
3. Conrad, H. E. (1989) *Ann. N.Y. Acad. Sci.* **556**, 18–28.
4. Ernst, S., Langer, R., Cooney, C. L. & Sasisekharan, R. (1995) *CRC Crit. Rev. Biochem. Mol. Biol.* **30**, 387–444.
5. Linhardt, R. J., Rice, K. G., Kim, Y. S., Lohse, D. L., Wang, H. M. & Loganathan, D. (1988) *Biochem. J.* **254**, 781–787.
6. Sasisekharan, R., Moses, M. A., Nugent, M. A., Cooney, C. L. & Langer, R. (1994) *Proc. Natl. Acad. Sci. USA* **91**, 1524–1528.
7. Binari, R. C., Staveley, B. E., Johnson, W. A., Godavarti, R., Sasisekharan, R. & Manoukian, A. S. (1997) *Development (Cambridge, U.K.)* **124**, 2623–2632.
8. Sutton, C. W., O'Neil, J. A. & Cottrell, J. S. (1994) *Anal. Biochem.* **218**, 34–46.
9. Rhomberg, A. J., Ernst, S., Sasisekharan, R. & Biemann, K. (1998) *Proc. Natl. Acad. Sci. USA* **95**, 4176–4181.
10. Ernst, S., Rhomberg, A. J., Biemann, K. & Sasisekharan, R. (1998) *Proc. Natl. Acad. Sci. USA* **95**, 4182–4187.
11. Nader, H. B. (1990) *J. Biol. Chem.* **265**, 16807–16813.
12. Moffat, C. F., McLean, M. W., Long, W. F. & Williamson, F. B. (1991) *Eur. J. Biochem.* **202**, 531–541.
13. Desai, U. R., Wang, H.-M. & Linhardt, R. J. (1993) *Arch. Biochem. Biophys.* **306**, 461–468.
14. Linhardt, R. J., Turnbull, J. E., Wang, H. M., Loganathan, D. & Gallagher, J. T. (1990) *Biochemistry* **29**, 2611–2617.
15. Sugahara, K., Tohno-oko, R., Yamada, S., Khoo, K. H., Morris, H. R. & Dell, A. (1994) *Glycobiology* **4**, 535–544.
16. Godavarti, R. & Sasisekharan, R. (1996) *Biochem. Biophys. Res. Commun.* **229**, 770–777.
17. Shriver, Z., Hu, Y., Pojasek, K. & Sasisekharan, R. (1998) *J. Biol. Chem.* **273**, 22904–22912.
18. Xiang, F. & Beavis, R. C. (1994) *Rapid Commun. Mass Spectrom.* **8**, 199–204.
19. Juhasz, P. & Biemann, K. (1994) *Carbohydr. Res.* **270**, 131–147.
20. Vestal, M. L., Juhasz, P. & Martin, S. A. (1995) *Rapid Commun. Mass Spectrom.* **9**, 1044–1050.
21. Shriver, Z., Hu, Y. & Sasisekharan, R. (1998) *J. Biol. Chem.* **273**, 10160–10167.